# Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

> **NCT02177500** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 327 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan + hydrochlorothiazide
- **DRUG:** Telmisartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02177500
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2000-05
- **Final completion:** —
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177500, "Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02177500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*